Haoyuan Pharmaceutical released its 2026 interim report. The company's total operating revenue was 1.648 billion yuan, and net profit attributable to the parent company was 171 million yuan. Net cash inflow from operating activities was 77.0646 million yuan, ranking 18th among disclosed peer companies. The company's latest asset-liability ratio was 50.01%, up 0.06 percentage points from the previous quarter and up 2.16 percentage points from the same period last year. The latest gross margin was 50.76%, down 1.66 percentage points from the previous quarter. The latest return on equity was 5.17%, and diluted earnings per share was 0.81 yuan. The company had 15,900 shareholders, and the top ten shareholders held 111 million shares, accounting for 52.13% of the total share capital.
Shanghai Haoyuan Chemexpress Co. Ltd. ACompany reports net profit of 171 million yuan in interim report.
